Advertisement

Molecular Biotechnology

, Volume 57, Issue 2, pp 155–159 | Cite as

Absolute qPCR for Measuring Telomere Length in Bone Marrow Samples of Plasma Cell Disorders

  • Julieta PaneroEmail author
  • Nathan J. O’Callaghan
  • Michael Fenech
  • Irma Slavutsky
Research

Abstract

Telomere length (TL) is currently used as an emerging biomarker in understanding the development/progression of hematological malignancies. The absolute quantitative PCR (qPCR) methodology has allowed the study of TL from a variety of mammalian tissues, but it has not been tested for bone marrow (BM) samples. In this study, we have examined the relationship between TL data generated by absolute qPCR versus those obtained by terminal restriction fragments (TRF) in 102 BM samples from patients with plasma cell disorders. A significant linear correlation between both methodologies was observed (p < 0.0001; r 2 = 0.70). Results were also analyzed in relation to clinical characteristics and significant associations between telomere shortening and parameters of adverse prognosis were observed. Furthermore, another set of 47 BM samples from patients with low quantity of DNA for TRF assay were suitably analyzed by qPCR, indicating the usefulness of the absolute qPCR methodology for the inclusion of patients with scarce material to the study. Taken together, these findings are of interest considering the importance of telomere dysfunction in the pathogenesis of cancer and give a new alternative to measure TL in hematologic disorders with substantial time and cost savings.

Keywords

Telomere length Absolute quantification Bone marrow samples Multiple myeloma MGUS 

Notes

Acknowledgments

This work was supported by Grants from the National Research Council (CONICET), the National Agency of Scientific and Technical Promotion (ANPCyT), and the Bunge and Born Foundation.

Conflict of interest

No competing financial interests exist.

Supplementary material

12033_2014_9811_MOESM1_ESM.doc (43 kb)
Supplementary material 1 (DOC 43 kb)
12033_2014_9811_MOESM2_ESM.doc (156 kb)
Supplementary material 2 (DOC 156 kb)

References

  1. 1.
    Counter, C. M., Avilion, A. A., LeFeuvre, C. E., et al. (1992). Telomere shortening associated with chromosome instability is arrested in immortal cells which express telomerase activity. EMBO Journal, 11, 1921–1929.Google Scholar
  2. 2.
    Wu, X., Amos, C. I., Zhu, Y., et al. (2003). Telomere dysfunction: A potential cancer predisposition factor. Journal of the National Cancer Institute, 95, 1211–1218.CrossRefGoogle Scholar
  3. 3.
    Hahn, W. C. (2003). Role of telomeres and telomerase in the pathogenesis of human cancer. Journal of Clinical Oncology, 21, 2034–2043.CrossRefGoogle Scholar
  4. 4.
    Stewart, S. A., & Weinberg, R. A. (2006). Telomeres: Cancer to human aging. Annual Review of Cell and Developmental Biology, 22, 531–557.CrossRefGoogle Scholar
  5. 5.
    Allshire, R. C., Dempster, M., & Hastie, N. D. (1989). Human telomeres contain at least three types of G-rich repeat distributed non-randomly. Nucleic Acids Research, 17, 4611–4627.CrossRefGoogle Scholar
  6. 6.
    Cawthon, R. M. (2002). Telomere measurement by quantitative PCR. Nucleic Acids Research, 30, e47.CrossRefGoogle Scholar
  7. 7.
    O’Callaghan, N., Dhillon, V., Thomas, P., & Fenech, M. (2008). A quantitative real-time PCR method for absolute telomere length. BioTechniques, 44, 807–809.CrossRefGoogle Scholar
  8. 8.
    O’Callaghan, N., & Fenech, M. (2011). A quantitative PCR method for measuring absolute telomere length. Biological Procedures Online, 13, 3.CrossRefGoogle Scholar
  9. 9.
    Folini, M., Venturini, L., Cimino-Reale, G., & Zaffaroni, N. (2011). Telomeres as targets for anticancer therapies. Expert Opinion on Therapeutic Targets, 15, 579–593.Google Scholar
  10. 10.
    Greipp, P. R., San Miguel, J., Durie, B. G., et al. (2005). International staging system for multiple myeloma. Journal of Clinical Oncology, 23, 3412–3420.CrossRefGoogle Scholar
  11. 11.
    Cottliar, A., Pedrazzini, E., Corrado, C., Engelberger, M. I., Narbaitz, M., & Slavutsky, I. (2003). Telomere shortening in patients with plasma cell disorders. European Journal of Haematology, 71, 334–340.CrossRefGoogle Scholar
  12. 12.
    Baird, D. M. (2005). New developments in telomere length analysis. Experimental Gerontology, 40, 363–368.CrossRefGoogle Scholar
  13. 13.
    Wu, K. D., Orme, L. M., Shaughnessy, J, Jr, Jacobson, J., Barlogie, B., & Moore, M. A. (2003). Telomerase and telomere length in multiple myeloma: Correlations with disease heterogeneity, cytogenetic status, and overall survival. Blood, 101, 4982–4989.CrossRefGoogle Scholar
  14. 14.
    Panero, J., Arbelbide, J., Fantl, D., Rivello, H. G., Kohan, D., & Slavutsky, I. (2010). Altered mRNA expression of telomere-associated genes in monoclonal gammopathy of undetermined significance and multiple myeloma. Molecular Medicine, 16, 471–478.CrossRefGoogle Scholar
  15. 15.
    Jones, C. H., Pepper, C., & Baird, D. M. (2012). Telomere dysfunction and its role in haematological cancer. British Journal of Haematology, 156, 573–587.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  • Julieta Panero
    • 1
    Email author
  • Nathan J. O’Callaghan
    • 2
  • Michael Fenech
    • 2
  • Irma Slavutsky
    • 1
  1. 1.Laboratorio de Genética de Neoplasias Linfoides, Instituto de Medicina Experimental (IMEX)CONICET-Academia Nacional de MedicinaBuenos AiresArgentina
  2. 2.Commonwealth Scientific and Industrial Research Organization (CSIRO)-Food and Nutritional SciencesAdelaideAustralia

Personalised recommendations